CoChat

UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis

Open access
Abbas, Nadir, Culver, Emma L., Thorburn, Douglas, Halliday, Neil, Crothers, Hannah, Dyson, Jessica K., Phaw, April, Aspinall, Richard, Khakoo, Salim I., Kallis, Yiannis, Smith, Belinda, Patanwala, Imran, McCune, Anne, Chimakurthi, Chenchu R., Hegade, Vinod, Orrell, Michael, Jones, Rebecca, Mells, George, Thain, Colette, Thain, Robert-Mitchell, Jones, David, Hirschfield, Gideon, Trivedi, Palak J. · 2023 · Clinical Gastroenterology and Hepatology
Cited by 39

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS: Thirty-to-forty percent of patients with primary biliary cholangitis inadequately respond to ursodeoxycholic acid. Our aim was to assemble national, real-world data on the effectiveness of obeticholic acid (OCA) as a second-line treatment, alongside non-licensed therapy with fibric acid derivatives (bezafibrate or fenofibrate). METHODS: This was a nationwide observational cohort study conducted from August 2017 until June 2021. RESULTS: We accrued data from 457 patients; 349 treated with OCA and 108 with fibric acid derivatives. At baseline/pre-treatment, individuals in the OCA group manifest higher risk features compared with those taking fibric acid derivatives, evidenced by more elevated alkaline phosphatase values, and a larger proportion of individuals with cirrhosis, abnormal bilirubin, prior non-response to ursodeoxycholic acid, and elastography readings >9.6kPa (P < .05 for all). Overall, 259 patients (OCA) and 80 patients (fibric acid derivatives) completed 12 months of second-line therapy, yielding a dropout rate of 25.7% and 25.9%, respectively. At 12 months, the magnitude of alkaline phosphatase reduction was 29.5% and 56.7% in OCA and fibric acid groups (P < .001). Conversely, 55.9% and 36.4% of patients normalized serum alanine transaminase and bilirubin in the OCA group (P < .001). The proportion with normal alanine transaminase or bilirubin values in the fibric acid group was no different at 12 months compared with baseline. Twelve-month biochemical response rates were 70.6% with OCA and 80% under fibric acid treatment (P = .121). Response rates between treatment groups were no different on propensity-score matching or on sub-analysis of high-risk groups defined at baseline. CONCLUSION: Across the population of patients with primary biliary cholangitis in the United Kingdom, rates of biochemical response and drug discontinuation appear similar under fibric acid and OCA treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2022.07.038

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 16

  1. Iwasaki, 1999, Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis, Hepatol Res, 16, 12, 10.1016/S1386-6346(99)00033-9 · DOI
  2. Corpechot, 2018, A placebo-controlled trial of bezafibrate in primary biliary cholangitis, N Engl J Med, 378, 2171, 10.1056/NEJMoa1714519 · DOI · Paper page
  3. Murillo Perez, 2020, Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase, Am J Gastroenterol, 115, 1066, 10.14309/ajg.0000000000000557 · DOI · Paper page
  4. Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI · Paper page
  5. Reig, 2021, Obeticholic acid and fibrates in primary biliary cholangitis: comparative effects in a multicentric observational study, Am J Gastroenterol, 116, 2250, 10.14309/ajg.0000000000001343 · DOI · Paper page
  6. Eaton, 2020, Liver injury in patients with cholestatic liver disease treated with obeticholic acid, Hepatology, 71, 1511, 10.1002/hep.31017 · DOI · Paper page
  7. Alrubaiy, 2019, PBC-10: a short quality of life measure for clinical screening in primary biliary cholangitis, Aliment Pharmacol Ther, 50, 1223, 10.1111/apt.15554 · DOI
  8. Hirschfield, 2018, The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines, Gut, 67, 1568, 10.1136/gutjnl-2017-315259 · DOI · Paper page
  9. 2017, Obeticholic acid for treating primary biliary cholangitis, Final Apprais Determ
  10. Corpechot, 2012, Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis, Hepatology, 56, 198, 10.1002/hep.25599 · DOI · Paper page
  11. Lammers, 2014, Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study, Gastroenterology, 147, 1338, 10.1053/j.gastro.2014.08.029 · DOI · Paper page
  12. Nevens, 2016, A placebo-controlled trial of obeticholic acid in primary biliary cholangitis, N Engl J Med, 375, 631, 10.1056/NEJMoa1509840 · DOI · Paper page
  13. Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI · Paper page
  14. Harms, 2019, Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis, J Hepatol, 71, 357, 10.1016/j.jhep.2019.04.001 · DOI · Paper page
  15. Carbone, 2018, Pre-treatment prediction of response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis: the UDCA Response Score, Lancet Gastroenterol Hepatol, 3, 626, 10.1016/S2468-1253(18)30163-8 · DOI · Paper page
  16. Ho, 2011, MatchIt: nonparametric preprocessing for parametric causal inference, J Stat Softw, 42, 1

Cited by

See all 39

Metadata

Authors
Abbas, N., Culver, E. L., Thorburn, D., Halliday, N., Crothers, H., Dyson, J. K., Phaw, A., Aspinall, R., Khakoo, S. I., Kallis, Y., Smith, B., Patanwala, I., McCune, A., Chimakurthi, C. R., Hegade, V., Orrell, M., Jones, R., Mells, G., Thain, C., Thain, R.-M., Jones, D., Hirschfield, G., & Trivedi, P. J.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2023-06
Volume
21
Issue
6
Pages
1561-1570.e13
ISSN
1542-3565 (ISSN-L)
OpenAlex
W4291708356
Cited by
39
References
21
FWCI
4.34
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis. https://app.cochat.ai/papers/10.1016/j.cgh.2022.07.038
The paper
Abbas, N., Culver, E. L., Thorburn, D., Halliday, N., Crothers, H., Dyson, J. K., Phaw, A., Aspinall, R., Khakoo, S. I., Kallis, Y., Smith, B., Patanwala, I., McCune, A., Chimakurthi, C. R., Hegade, V., Orrell, M., Jones, R., Mells, G., Thain, C., . . . Trivedi, P. J. (2023). UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2022.07.038

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.